171 related articles for article (PubMed ID: 21940784)
21. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
[TBL] [Abstract][Full Text] [Related]
22. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Felip E; Concha Á; de Castro J; Gómez-Román J; Garrido P; Ramírez J; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2015 Feb; 17(2):103-12. PubMed ID: 25351175
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.
Dietel M; Bubendorf L; Dingemans AM; Dooms C; Elmberger G; García RC; Kerr KM; Lim E; López-Ríos F; Thunnissen E; Van Schil PE; von Laffert M
Thorax; 2016 Feb; 71(2):177-84. PubMed ID: 26530085
[TBL] [Abstract][Full Text] [Related]
24. SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition.
Trigo Pérez JM; Garrido López P; Felip Font E; Isla Casado D;
Clin Transl Oncol; 2010 Nov; 12(11):735-41. PubMed ID: 20974565
[TBL] [Abstract][Full Text] [Related]
25. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
[TBL] [Abstract][Full Text] [Related]
26. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
27. Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer.
Lennes IT; Lynch TJ
Clin Lung Cancer; 2009 Sep; 10(5):341-6. PubMed ID: 19808192
[TBL] [Abstract][Full Text] [Related]
28. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
Majem M; Juan O; Insa A; Reguart N; Trigo JM; Carcereny E; García-Campelo R; García Y; Guirado M; Provencio M
Clin Transl Oncol; 2019 Jan; 21(1):3-17. PubMed ID: 30446985
[TBL] [Abstract][Full Text] [Related]
29. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.
Pallis AG; Gridelli C; van Meerbeeck JP; Greillier L; Wedding U; Lacombe D; Welch J; Belani CP; Aapro M
Ann Oncol; 2010 Apr; 21(4):692-706. PubMed ID: 19717538
[TBL] [Abstract][Full Text] [Related]
30. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
31. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; D'Amico TA; DeCamp M; Dilling TJ; Dowell J; Gettinger S; Grotz TE; Gubens MA; Hegde A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Ng T; Otterson GA; Pacheco JM; Patel SP; Riely GJ; Riess J; Schild SE; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory K; Hughes M
J Natl Compr Canc Netw; 2022 May; 20(5):497-530. PubMed ID: 35545176
[TBL] [Abstract][Full Text] [Related]
32. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Eberhardt WE; De Ruysscher D; Weder W; Le Péchoux C; De Leyn P; Hoffmann H; Westeel V; Stahel R; Felip E; Peters S;
Ann Oncol; 2015 Aug; 26(8):1573-88. PubMed ID: 25897013
[TBL] [Abstract][Full Text] [Related]
33. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
Schneider BJ; Daly ME; Kennedy EB; Antonoff MB; Broderick S; Feldman J; Jolly S; Meyers B; Rocco G; Rusthoven C; Slotman BJ; Sterman DH; Stiles BM
J Clin Oncol; 2018 Mar; 36(7):710-719. PubMed ID: 29106810
[TBL] [Abstract][Full Text] [Related]
35. The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture.
Vescio RA; Connors KM; Bordin GM; Robb JA; Youngkin T; Umbreit JN; Hoffman RM
Cancer Res; 1990 Sep; 50(18):6095-9. PubMed ID: 2168289
[TBL] [Abstract][Full Text] [Related]
36. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
37. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
38. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
[TBL] [Abstract][Full Text] [Related]
39. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
[TBL] [Abstract][Full Text] [Related]
40. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
